Trial Profile
A Randomized, Open-label, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2019
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Dong-A ST
- 19 Dec 2019 Status changed from recruiting to completed.
- 13 Dec 2018 Planned End Date changed from 31 Oct 2018 to 31 Aug 2019.
- 13 Dec 2018 Planned primary completion date changed from 31 Aug 2018 to 31 Dec 2018.